Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: A case-control study

npj Schizophrenia

Volumn 1, Issue 1, 2015, Pages

  Colizzi, Marco ^a,b   Iyegbe, Conrad ^b   Powell, John ^b   Blasi, Giuseppe ^a   Bertolino, Alessandro ^a,c   Murray, Robin M ^b   Di Forti, Marta ^b  

^a UNIVERSITY OF BARI   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AKT 1 GENE; ALLELE; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DRD 2 GENE; ETHNICITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; SELF REPORT;

EID: 85056226616     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/npjschz.2015.25     Document Type: Article

References (9)

1. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72(10): 811-816.
2. Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A et al. Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull, e-pub ahead of print 201510.1093/schbul/sbv032.
3. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108(3): 1158-1163.
4. Van Winkel R. Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011; 68: 148-157.
5. Colizzi M, Fazio L, Ferranti L, Porcelli A, Masellis R, Marvulli D et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related behavior. Neuropsychopharmacology 2015; 40(3): 640-649.
6. Murray RM, Mehta M, Di Forti M. Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol Psychiatry 2014; 75(6): 430-431.
7. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of d-9-Tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012; 17: 1152-1155.
8. Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, Romano R et al. Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS ONE 2010; 5(2): e9348.
9. Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 2013; 18(8): 909-915.